Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV

  • Hanie Safarpour
    Infectious and Tropical Diseases Research Center
  • Muge Cevik
    Division of Infection and Global Health Research, School of Medicine, University of St Andrews, Fife, UK
  • Mehdi Zarean
    Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Aleksandra Barac
    Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Kareem Hatam-Nahavandi
    Iranshahr University of Medical Sciences, Iranshahr
  • Mohammad T. Rahimi
    School of Medicine, Shahroud University of Medical Sciences, Shahroud
  • Hossein Bannazadeh Baghi
    Immunology Research Center
  • Tohid J. Koshki
    Department of Statistics and Epidemiology, Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz
  • Abdol S. Pagheh
    Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand
  • Firooz Shahrivar
    Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran
  • Mina Ebrahimi
    Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ehsan Ahmadpour
    Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran.

この論文をさがす

説明

<jats:sec> <jats:title>Objective:</jats:title> <jats:p> <jats:italic toggle="yes">Toxoplasma</jats:italic> infection remains as the most common cause of focal brain lesions among people living with HIV (PLHIV) despite the decline in opportunistic infections with the introduction of antiretroviral treatment. This study was conducted to provide a summary of evidence about the seroprevalence of <jats:italic toggle="yes">Toxoplasma gondii</jats:italic> and prevalence of active <jats:italic toggle="yes">T. gondii</jats:italic> infection and associated risk factors among PLHIV.</jats:p> </jats:sec> <jats:sec> <jats:title>Design:</jats:title> <jats:p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Scopus, PubMed, Science Direct and EMBASE were searched from <jats:italic toggle="yes">1997 to July 2018.</jats:italic> All peer-reviewed original research articles describing <jats:italic toggle="yes">T. gondii</jats:italic> infection among PLHIV with different diagnostic methods were included.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Incoherence and heterogeneity between studies were quantified by <jats:italic toggle="yes">I</jats:italic> <jats:sup>2</jats:sup> index and Cochran's <jats:italic toggle="yes">Q</jats:italic> test. Publication and population bias were assessed with funnel plots and Egger's regression asymmetry test. All statistical analyses were performed using StatsDirect.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>In total, 111 studies from 37 countries assessing 66 139 blood samples were included in this study. The pooled prevalence of <jats:italic toggle="yes">T. gondii</jats:italic> infection among PLHIV was 3.24% by IgM and 26.22% by molecular methods using the random-effects model. Pooled seroprevalence of <jats:italic toggle="yes">T. gondii</jats:italic> by IgG was 44.22%. There was a relationship between <jats:italic toggle="yes">Toxoplasma</jats:italic> prevalence and sex, raw meat consumption, contact with cat and knowledge about toxoplasmosis.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>High <jats:italic toggle="yes">Toxoplasma</jats:italic> seroprevalence among PLHIV observed in this study emphasizes the need for implementing screening and prophylaxis tailored to the local context. Owing to the serious and significant clinical manifestations of the parasite in case of reactivation, early identification of seropositivity for initiating prophylaxis among those with a CD4<jats:sup>+</jats:sup> cell count of less than 200 cells/ml is recommended.</jats:p> </jats:sec>

収録刊行物

  • AIDS

    AIDS 34 (3), 469-474, 2020-03-01

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ